<DOC>
	<DOCNO>NCT00586846</DOCNO>
	<brief_summary>This study design test safety feasibility simultaneous administration biphosphonate chemotherapy treatment osteosarcoma newly diagnose patient .</brief_summary>
	<brief_title>Phase II Study Chemotherapy Pamidronate Treatment Newly Diagnosed Osteosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Newly diagnose , previously untreated biopsy proven highgrade osteosarcoma . Patient undergone definitive surgical resection primary surgery still eligible participation study . No prior chemotherapy radiation therapy Adequate renal function : creatinine &lt; = 1.5 upper limit normal Adequate liver function define bilirubin &lt; = 1.5 X upper limit normal AST &lt; = 3 X upper limit normal institutional range Adequate hematopoietic function define platelet count &gt; = 100,000/ram3 absolute neutrophil count &gt; = 1,000/mm3 . Adequate cardiac function define shorten fraction &gt; = 28 % echocardiogram OR ejection fraction &gt; = 50 % radionuclide angiogram Performance status &lt; = 2 Prior history cancer Prior treatment cancer Prior history Paget 's disease Prior history pericarditis , myocarditis , symptomatic arrhythmia symptomatic cardiac conduction abnormality Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Cisplatin</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>03-074</keyword>
</DOC>